We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Effects of Oral Tolvaptan in Patients Hospitalized for Worsening Heart Failure.
- Authors
Konstam, Marvin A.; Gheorghiade, Mihai; Burnett, Jr., John C.; Grinfeld, Liliana; Maggioni, Aldo P.; Swedberg, Karl; Udelson, James E.; Zannad, Faiez; Cook, Thomas; Ouyang, John; Zimmer, Christopher; Orlandi, Cesare
- Abstract
The article discusses the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan, a randomized controlled study that examined the health effects of tolvaptan in patients who were hospitalized with heart failure. Patients in the study were given either oral tolvaptan or a placebo. Tolvaptan is a vasopressin V2 receptor blocker. The clinical trial found that the use of tolvaptan in the treatment of patients with heart failure did not have an effect on the long-term mortality or morbidity related to heart failure.
- Subjects
HEART failure treatment; HEART diseases; THERAPEUTICS; MEDICAL research; RANDOMIZED controlled trials; VASOPRESSIN; PITUITARY hormones
- Publication
JAMA: Journal of the American Medical Association, 2007, Vol 297, Issue 12, p1319
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.297.12.1319